NASDAQ:TGTX 3 November 2025 - 11 January 2026

TG Therapeutics shares fell 7% to $28.35 by late Friday, reversing early gains and hitting session lows. The drop comes ahead of CEO Michael Weiss’s scheduled presentation at the J.P. Morgan Healthcare Conference on Jan. 13. Traders are watching for updates on Briumvi demand and 2026 plans.

TG Therapeutics reported Q3 2025 revenue of $161.7 million, up 92.8% year-over-year, driven by Briumvi sales. Net income reached $390.9 million, boosted by a $365 million tax benefit. Management raised full-year revenue guidance to $600 million. TGTX shares trade near $35, about 18% higher year-to-date but 15% below their 52-week high.